A new research consortium under NHGRI funding is building a population genomic screening network to study real-world clinical implementation and outcomes. The initiative, called the Population Genomic Screening Network, will enroll patients in primary care settings and analyze what happens after positive results across a shared protocol. The network is designed to test feasibility, clinical outcomes, and the full cycle of implementation—not just test performance—while sequencing samples through Baylor College of Medicine and coordinating through the University of Washington. Investigators outlined CDC Tier 1 conditions among the initial target set. For biotech and diagnostics developers, the trial framework is a critical signal that implementation science is becoming central to genomic evidence generation, shaping how platforms are adopted and reimbursed.